Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
MindMed files a "Base Shelf Prospectus" with the SEC.
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
Cybin announces senior management changes as it moves into the next stage of its evolution.
MindMed announces its year-end results for 2020, cash-on-hand at US$161 million, including a total cash burn for 2020 of US$24.2 million.
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?
Lobe Sciences becomes the latest addition to the Horizons psychedelics ETF (PSYK).
The COVID pandemic is making the need for psychedelic drugs and the commercial potential of the industry much greater. But there is a catch.
Cybin inks a drug development agreement with Catalent, "the leading global provider" of drug delivery, development and manufacturing solutions.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now